Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1982 1
1988 1
1989 2
1993 1
1995 1
1996 3
1997 3
1998 4
1999 4
2000 3
2001 4
2002 1
2003 5
2004 3
2005 2
2007 4
2008 2
2009 2
2010 5
2011 1
2012 2
2013 4
2014 1
2015 2
2016 3
2017 4
2018 1
2019 2
2021 6
2022 3
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
Hokusai-VTE Investigators; Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Hokusai-VTE Investigators, et al. N Engl J Med. 2013 Oct 10;369(15):1406-15. doi: 10.1056/NEJMoa1306638. Epub 2013 Aug 31. N Engl J Med. 2013. PMID: 23991658 Free article. Clinical Trial.
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Lee AY, et al. Among authors: baker ri. N Engl J Med. 2003 Jul 10;349(2):146-53. doi: 10.1056/NEJMoa025313. N Engl J Med. 2003. PMID: 12853587 Free article. Clinical Trial.
Antiplatelet drugs.
Baker RI, Hankey GJ. Baker RI, et al. Med J Aust. 1999 Apr 19;170(8):379-82. doi: 10.5694/j.1326-5377.2003.tb05361.x. Med J Aust. 1999. PMID: 10327952 Review. No abstract available.
Haematology.
Baker RI, Street AM, Taylor KM. Baker RI, et al. Med J Aust. 2002 Jan 7;176(1):19. doi: 10.5694/j.1326-5377.2002.tb04252.x. Med J Aust. 2002. PMID: 11840919 No abstract available.
Economy class syndrome.
Gallus AS, Baker RI. Gallus AS, et al. Among authors: baker ri. Med J Aust. 2001 Mar 19;174(6):264-5. doi: 10.5694/j.1326-5377.2001.tb143263.x. Med J Aust. 2001. PMID: 11297109 No abstract available.
The platelet Fc receptor, FcγRIIa.
Qiao J, Al-Tamimi M, Baker RI, Andrews RK, Gardiner EE. Qiao J, et al. Among authors: baker ri. Immunol Rev. 2015 Nov;268(1):241-52. doi: 10.1111/imr.12370. Immunol Rev. 2015. PMID: 26497525 Review.
Current state and novel approaches of antiplatelet therapy.
Metharom P, Berndt MC, Baker RI, Andrews RK. Metharom P, et al. Among authors: baker ri. Arterioscler Thromb Vasc Biol. 2015 Jun;35(6):1327-38. doi: 10.1161/ATVBAHA.114.303413. Epub 2015 Apr 2. Arterioscler Thromb Vasc Biol. 2015. PMID: 25838432 Review.
VWF-ADAMTS13 axis dysfunction in children with sickle cell disease treated with hydroxycarbamide vs blood transfusion.
Fogarty H, Ahmad A, Atiq F, Doherty D, Ward S, Karampini E, Rehill A, Leon G, Byrne C, Geoghegan R, Conroy H, Byrne M, Budde U, Schneppenheim S, Sheehan C, Ngwenya N, Baker RI, Preston RJS, Tuohy E, McMahon C, O'Donnell JS. Fogarty H, et al. Among authors: baker ri. Blood Adv. 2023 Nov 28;7(22):6974-6989. doi: 10.1182/bloodadvances.2023010824. Blood Adv. 2023. PMID: 37773926 Free PMC article.
84 results